ATE83666T1 - Zusammensetzungen zur verhuetung sekundaeren grauen stars. - Google Patents

Zusammensetzungen zur verhuetung sekundaeren grauen stars.

Info

Publication number
ATE83666T1
ATE83666T1 AT87309722T AT87309722T ATE83666T1 AT E83666 T1 ATE83666 T1 AT E83666T1 AT 87309722 T AT87309722 T AT 87309722T AT 87309722 T AT87309722 T AT 87309722T AT E83666 T1 ATE83666 T1 AT E83666T1
Authority
AT
Austria
Prior art keywords
cytotoxic agent
compositions
prevention
instilled
secondary gray
Prior art date
Application number
AT87309722T
Other languages
English (en)
Inventor
Dominic Man-Kit Lam
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE83666T1 publication Critical patent/ATE83666T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Liquid Crystal Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87309722T 1986-11-04 1987-11-03 Zusammensetzungen zur verhuetung sekundaeren grauen stars. ATE83666T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92731886A 1986-11-04 1986-11-04
EP87309722A EP0267005B1 (de) 1986-11-04 1987-11-03 Zusammensetzungen zur Verhütung sekundären grauen Stars

Publications (1)

Publication Number Publication Date
ATE83666T1 true ATE83666T1 (de) 1993-01-15

Family

ID=25454561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87309722T ATE83666T1 (de) 1986-11-04 1987-11-03 Zusammensetzungen zur verhuetung sekundaeren grauen stars.

Country Status (12)

Country Link
EP (1) EP0267005B1 (de)
JP (1) JPH07121878B2 (de)
AT (1) ATE83666T1 (de)
AU (1) AU608257B2 (de)
CA (1) CA1338777C (de)
DE (1) DE3783211T2 (de)
DK (1) DK575487A (de)
ES (1) ES2053561T3 (de)
FI (1) FI95203C (de)
GR (1) GR3007052T3 (de)
IE (1) IE60436B1 (de)
NO (1) NO173974C (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
WO1995003783A1 (en) * 1990-03-06 1995-02-09 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044167A3 (de) * 1980-07-14 1982-04-21 The Regents Of The University Of California Durch einen Antikörper gerichtetes zytotoxisches Mittel
US4432751A (en) * 1982-03-05 1984-02-21 Baylor College Of Medicine Monoclonal antibodies against lens epithelial cells and preventing proliferation of remnant lens epithelial cells after extracapsular extraction
DE3483996D1 (de) * 1983-09-15 1991-02-28 Univ Leland Stanford Junior Allotransplantat mit verminderter immunogenitaet und verfahren und reagenz fuer seine herstellung.
EP0173648A3 (de) * 1984-08-30 1988-04-27 Ciba-Geigy Ag Monoklonale Antikörper gegen Glykokonjugate, Verfahren zu ihrer Herstellung und Verwendungen
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins

Also Published As

Publication number Publication date
EP0267005A3 (en) 1989-11-08
FI95203B (fi) 1995-09-29
FI874852A (fi) 1988-05-05
NO874569L (no) 1988-05-05
JPS63211239A (ja) 1988-09-02
FI874852A0 (fi) 1987-11-03
DK575487A (da) 1988-05-05
JPH07121878B2 (ja) 1995-12-25
NO173974C (no) 1994-03-02
DK575487D0 (da) 1987-11-03
NO173974B (no) 1993-11-22
EP0267005A2 (de) 1988-05-11
DE3783211T2 (de) 1993-04-29
IE872977L (en) 1988-05-04
GR3007052T3 (de) 1993-07-30
FI95203C (fi) 1996-01-10
IE60436B1 (en) 1994-07-13
AU8066687A (en) 1988-05-05
DE3783211D1 (de) 1993-02-04
CA1338777C (en) 1996-12-10
AU608257B2 (en) 1991-03-28
ES2053561T3 (es) 1994-08-01
EP0267005B1 (de) 1992-12-23
NO874569D0 (no) 1987-11-03

Similar Documents

Publication Publication Date Title
PT75777A (en) Process for the preparation of a composition for topical treatment of glaucoma and ocular hypertension
ES8507573A1 (es) Procedimiento para la fabricacion de fracciones de acido hialuronico
GB1502082A (en) Orthoester polymers
ATE188872T1 (de) Verfahren zur verhinderung der trübung der hinteren linsenkapsel
ATE147619T1 (de) Opthalmische zusammensetzungen enthaltend ein cyclosporin
ES474047A1 (es) Procedimiento para preparar un cebo para moscas sinantropas
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
GB615744A (en) Improvements in or relating to duplicating
IE811654L (en) Ophthalmic composition
ATE83666T1 (de) Zusammensetzungen zur verhuetung sekundaeren grauen stars.
FI911131A (fi) Menetelmä viherkaihia estävien 3-aryylikarbonyyli-1-aminoalkyyli-1H-indoliyhdisteiden valmistamiseksi
IL86550A0 (en) Thiophene sulfonamides and ophthalmic compositions containing them
AU7039981A (en) Compositions and methods of lowering intraocular pressure in the hypertensive mammalian eye
GB810232A (en) Improvements in artificial intraocular lenses
Kassar et al. Effect of PMMA and silicone lens materials on normal rabbit corneal endothelium: An in vitro study
SE8103778L (sv) Oxytocinanaloger och sett for framstellning derav
SE7705812L (sv) Farmaceutiska ogonberedningar med langsam utsondring, innehallande kollagener samt sett for framstellning derav
EP0372071A4 (de) Monoklonale antikörper gegen linsenepithelzellen und methoden zur verhinderung des vermehrung übriggebliebener linsenepithelzellen nach extrakapsuläres extraktion.
SU648187A1 (ru) Состав дл консервировани роговиц человека
ADLER et al. PATHOLOGIC STUDY OF OCULAR LESIONS DUE TO LEWISITE (β-CHLOROVINYLDICHLOROARSINE): Changes With and Without BAL (2, 3-Dimercaptopropanol) Therapy
SU682446A1 (ru) Способ автоклавной выплавки серы
ES8503645A1 (es) Procedimiento de preparacion de carbamatos vinilicos
Loewenstein Sommerville-Large, LB Self inflicted eye injuries. Tr. Ophth Sot. U. Kingdom 67: 185-201, 1947. The author reported 375 cases of self-inflicted injury in India. Injury was com
RU93057936A (ru) Способ экстракции катаракты
FR2210405A1 (en) n-Tetrazolyl benzo(thio) pyran-2-carboxamides - antiallergens prepd. e.g. by cyclisation of corresp. azidoamidines

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee